3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
CNS
2
Thoracic
1
Other solid neoplasm
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Hodgkin Disease
36
Lymphoma
34
Lymphoma, Non-Hodgkin
24
Lymphoma, Large B-Cell, Diffuse
24
Lymphoma, Follicular
18
Lymphoma, B-Cell
16
Recurrence
15
Melanoma
14
Neoplasms
12
Mycosis Fungoides
9
Lymphoma, T-Cell
9
Breast Neoplasms
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Carcinoma, Non-Small-Cell Lung
8
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, T-Cell, Cutaneous
7
Lymphoma, B-Cell, Marginal Zone
7
Head and Neck Neoplasms
7
Sezary Syndrome
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Mantle-Cell
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Neoplasm Metastasis
5
Lymphoma, T-Cell, Peripheral
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Interventions
fludarabine
2
Cyclophosphamide
2
trametinib
1
sonidegib
1
ripretinib
1
ribociclib
1
pembrolizumab
1
keyhole-limpet hemocyanin
1
fludarabine phosphate
1
Therapeutics
1
Tetanus Toxoid
1
Stem Cell Transplantation
1
Sirolimus
1
Psychiatric Rehabilitation
1
Ocoxin
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Genistein
1
Gemcitabine
1
Filgrastim
1
Drug Therapy
1
Busulfan
1
Amplified Fragment Length Polymorphism Analysis
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
pembrolizumab
×
Lymphoid
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled